Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
Bone Metastases
Brain Cancer
Business Management
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Genitourinary Cancers
Head & Neck Cancers
Hematologic Oncology
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Non-Hodgkin Lymphoma
Oncology Nursing News
Patient Resources
Sarcomas/TGCT
Special Reports in Personalized Cancer Care
Supportive Care
Online CME
Interactive Publications
SELECT A TOPIC
CURRENT VIEW
All Specialties
▲
Education ▲
Education ▼
Register
|
Login
Conference Coverage
Videos
NewsNetwork
OncLive
®
TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
PER Conferences
Giants of Cancer Care
ISGIO
Webinars
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology
®
Neoadjuvant HER2+
More >>
OncLive TV: MaryBeth Freeman, MPH
<< Back to Our Featured Experts
Updated Screening Guidelines in Prostate Cancer
Oncology Specialists
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Abdulraheem Yacoub, MD
Ghanshyam Yadav, MD
Kosj Yamoah, MD
James C. Yang, MD
Jay Yang, MD
Zhi Zhang Yang, MD
Francis Yao, MD
James C. Yao, MD
Katharine Yao, MD
Stanley Yap, MD
Denise Yardley, MD
Denise A. Yardley, MD
Rozita Yarmand, PhD
Christopher A. Yasenchak, MD
Victor Y. Yazbeck, MD
Douglas Yee, MD
Todd A. Yezefski, MD
Ken Y. Yoneda, MD
Harry H. Yoon, MD
Jeff Yorio, MD
Anas Younes, MD
Guy Young, MD
Benjamin A. Youngblood, PhD
Evan Y. Yu, MD
Helena A. Yu, MD
James B. Yu, MD
Peter Yu, MD
RuiRong Yuan, MD, PhD
Bertram Yuh, MD
Rex Chin-Wei Yung, MD
Matthew Yurgelun, MD
Matthew B. Yurgelun, MD
OncLive News Network On Location: ASH 2019 Day 3
Trending Now
Residual Cancer Burden Predicts Patient Outcomes Across Breast Cancer Subtypes
Chemo-Free Regimen Matches Neoadjuvant Chemo in HR+/HER2- Breast Cancer
Expert Highlights Potential Markers of Nivolumab/Ipilimumab Response in Melanoma
Spartalizumab Plus Dabrafenib/Trametinib Impresses in
BRAF
+ Melanoma With Poor Prognosis
Publications
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
x
Subscribe